Gene therapy and immunotherapy as promising strategies to combat Huntington’s disease-associated neurodegeneration: emphasis on recent updates and future perspectives

References

• Kumar A, Kumar V, Singh K, et al. Therapeutic advances for huntington’s disease. Brain Sci. 2020;10(1): 43.
   PubMed Web of Science ®Google Scholar
• Smith AV, Tabrizi SJ. Therapeutic antisense targeting of huntingtin. DNA Cell Biol. 2020;39(2):154–158.
   PubMed Web of Science ®Google Scholar
• Shannon KM. Recent advances in the treatment of huntington’s disease: targeting DNA and RNA. CNS Drugs. 2020;34(3):219–228.
   PubMed Web of Science ®Google Scholar
• Bashir H. Emerging therapies in Huntington’s disease. Expert Rev Neurother. 2019;19(10):983–995.
   PubMed Web of Science ®Google Scholar
• Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach to Huntington’s disease. Nat Rev Neurosci. 2005;6(12):919–930.
   PubMed Web of Science ®Google Scholar
• Mestre TA. Recent advances in the therapeutic development for Huntington disease. Parkinsonism Relat Disord. 2019;59:125–130.
   PubMed Web of Science ®Google Scholar
• Dickey AS, La Spada AR. Therapy development in Huntington disease: from current strategies to emerging opportunities. Am J Med Genet A. 2018;176(4):842–861.
   PubMed Web of Science ®Google Scholar
• Caron NS, Dorsey ER, Hayden MR. Therapeutic approaches to Huntington disease: from the bench to the clinic. Nat Rev Drug Discov. 2018;17(10):729–750.
   PubMed Web of Science ®Google Scholar
• Fatoba O, Ohtake Y, Itokazu T, et al. Immunotherapies in Huntington’s disease and α-Synucleinopathies. Front Immunol. 2020;11:337.
   PubMed Web of Science ®Google Scholar
• Denis HL, David LS, Cicchetti F. Antibody-based therapies for Huntington’s disease: current status and future directions. Neurobiol Dis. 2019;132:104569.
   PubMed Web of Science ®Google Scholar
• Singh K, Roy I. Nucleic acid therapeutics in huntington’s disease. Recent Pat Biotechnol. 2019;13(3):187–206.
   PubMedGoogle Scholar
• Frank S. Treatment of Huntington’s disease. Neurotherapeutics. 2014;11(1):153–160.
   PubMed Web of Science ®Google Scholar
• Frank S. Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease. Neuropsychiatr Dis Treat. 2010;6:657–665.
   PubMed Web of Science ®Google Scholar
• Nayerossadat N, Maedeh T, Ali PA. Viral and nonviral delivery systems for gene delivery. Adv Biomed Res. 2012;1(1):27.
   PubMedGoogle Scholar
• Gray SJ, Woodard KT, Samulski RJ. Viral vectors and delivery strategies for CNS gene therapy. Ther Deliv. 2010;1(4):517–534.
   PubMedGoogle Scholar
• Saraiva J, Nobre RJ, de Almeida LP. Gene therapy for the CNS using AAVs: the impact of systemic delivery by AAV9. J Control Release. 2016;241:94–109.
   PubMed Web of Science ®Google Scholar
• Jayant RD, Sosa D, Kaushik A, et al. Current status of non-viral gene therapy for CNS disorders. Expert Opin Drug Deliv. 2016;13(10):1433–1434.
   PubMed Web of Science ®Google Scholar
• Colella P, Ronzitti G, Mingozzi F. Emerging issues in AAV-mediated in vivo gene therapy. Mol Ther Methods Clin Dev. 2018;8:87–104.
   PubMed Web of Science ®Google Scholar
• Wang D, Tai PW, Gao G. Adeno-associated virus vector as a platform for gene therapy delivery. Nat Rev Drug Discov. 2019;18:358–378.
   PubMed Web of Science ®Google Scholar
• Lee CS, Bishop ES, Zhang R, et al. Adenovirus-mediated gene delivery: potential applications for gene and cell-based therapies in the new era of personalized medicine. Genes Dis. 2017;4(2):43–63.
   PubMed Web of Science ®Google Scholar
• Badin RA, Binley K, Van Camp N, et al. Gene therapy for Parkinson’s disease: preclinical evaluation of optimally configured TH: CH1 fusion for maximal dopamine synthesis. Mol Ther Methods Clin Dev. 2019;14:206–216.
   PubMed Web of Science ®Google Scholar
• Ramamoorth M, Narvekar A. Non viral vectors in gene therapy-an overview. J clin diagn res: JCDR. 2015;9(4):GE01.
   PubMedGoogle Scholar
• Hardee CL, Arévalo-Soliz LM, Hornstein BD, et al. Advances in non-viral DNA vectors for gene therapy. Genes (Basel). 2017;8(2):65.
   Web of Science ®Google Scholar
• Lim M, Badruddoza AZ, Firdous J, et al. Engineered nanodelivery systems to Improve DNA vaccine technologies. Pharmaceutics. 2020;12(1):30.
   Web of Science ®Google Scholar
• Patil S, Gao YG, Lin X, et al. The development of functional non-viral vectors for gene delivery. Int J Mol Sci. 2019;20(21):5491.
   PubMed Web of Science ®Google Scholar
• Zhu L, Mahato RI. Lipid and polymeric carrier-mediated nucleic acid delivery. Expert Opin Drug Deliv. 2010;7(10):1209–1226.
   PubMed Web of Science ®Google Scholar
• Chen W, Hu Y, Ju D. Gene therapy for neurodegenerative disorders: advances, insights and prospects. Acta Pharm Sin B. 2020. DOI:https://doi.org/10.1016/j.apsb.2020.01.015.
   Web of Science ®Google Scholar
• Chery J. RNA therapeutics: rNAi and antisense mechanisms and clinical applications. Postdoc J. 2016;4(7):35–50.
   PubMedGoogle Scholar
• Paterson BM, Roberts BE, Kuff EL. Structural gene identification and mapping by DNA-mRNA hybrid-arrested cell-free translation. Proc Natl Acad Sci U S A. 1977;74(10):4370–4374.
   PubMed Web of Science ®Google Scholar
• Bajan S, Hutvagner G. RNA-based therapeutics: from antisense oligonucleotides to miRNAs. Cells. 2020;9(1):137.
   PubMed Web of Science ®Google Scholar
• Stein CA, Castanotto D. FDA-approved oligonucleotide therapies in 2017. Mol Ther. 2017;25(5):1069–1075.
   PubMed Web of Science ®Google Scholar
• Tabrizi SJ, Ghosh R, Leavitt BR. Huntingtin lowering strategies for disease modification in Huntington’s disease. Neuron. 2019;101(5):801–819.
   PubMed Web of Science ®Google Scholar
• Marxreiter F, Stemick J, Kohl Z. Huntingtin lowering strategies. Int J Mol Sci. 2020;21(6):2146.
   Web of Science ®Google Scholar
• Kaemmerer WF, Grondin RC. The effects of huntingtin-lowering: what do we know so far? Degener Neurol Neuromuscul Dis. 2019;9:3–17.
   PubMed Web of Science ®Google Scholar
• Wild EJ, Tabrizi SJ. Therapies targeting DNA and RNA in Huntington’s disease. Lancet Neurol. 2017;16(10):837–847.
   PubMed Web of Science ®Google Scholar
• Carroll JB, Warby SC, Southwell AL, et al. Potent and selective antisense oligonucleotides targeting single-nucleotide polymorphisms in the Huntington disease gene/allele-specific silencing of mutant huntingtin. Mol Ther. 2011;19(12):2178–2185.
   PubMed Web of Science ®Google Scholar
• Kordasiewicz HB, Stanek LM, Wancewicz EV, et al. Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. Neuron. 2012;74(6):1031–1044.
   PubMed Web of Science ®Google Scholar
• Stanek LM, Yang W, Angus S, et al. Antisense oligonucleotide-mediated correction of transcriptional dysregulation is correlated with behavioral benefits in the YAC128 mouse model of Huntington’s disease. J Huntingtons Dis. 2013;2(2):217–228.
   PubMedGoogle Scholar
• Østergaard ME, Southwell AL, Kordasiewicz H, et al. Rational design of antisense oligonucleotides targeting single nucleotide polymorphisms for potent and allele selective suppression of mutant Huntingtin in the CNS. Nucleic Acids Res. 2013;41(21):9634–9650.
   PubMed Web of Science ®Google Scholar
• Southwell AL, Skotte NH, Kordasiewicz HB, et al. In vivo evaluation of candidate allele-specific mutant huntingtin gene silencing antisense oligonucleotides. Mol Ther. 2014;22(12):2093–2106.
   PubMed Web of Science ®Google Scholar
• Evers MM, Tran HD, Zalachoras I, et al. Preventing formation of toxic N-terminal huntingtin fragments through antisense oligonucleotide-mediated protein modification. Nucleic Acid Ther. 2014;24(1):4–12.
   PubMed Web of Science ®Google Scholar
• Wang YL, Liu W, Wada E, et al. Clinico-pathological rescue of a model mouse of Huntington’s disease by siRNA. Neurosci Res. 2005;53(3):241–249.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Lebron E, Denovan-Wright EM, Nash K, et al. Intrastriatal rAAV-mediated delivery of anti-huntingtin shRNAs induces partial reversal of disease progression in R6/1 Huntington’s disease transgenic mice. Mol Ther. 2005;12(4):618–633.
   PubMed Web of Science ®Google Scholar
• Machida Y, Okada T, Kurosawa M, et al. rAAV-mediated shRNA ameliorated neuropathology in Huntington disease model mouse. Biochem Biophys Res Commun. 2006;343(1):190–197.
   PubMed Web of Science ®Google Scholar
• Huang B, Schiefer J, Sass C, et al. High-capacity adenoviral vector-mediated reduction of huntingtin aggregate load in vitro and in vivo. Hum Gene Ther. 2007;18(4):303–311.
   PubMed Web of Science ®Google Scholar
• Franich NR, Fitzsimons HL, Fong DM, et al. AAV vector–mediated RNAi of mutant huntingtin expression is neuroprotective in a novel genetic rat model of Huntington’s disease. Mol Ther. 2008;16(5):947–956.
   PubMed Web of Science ®Google Scholar
• Boudreau RL, McBride JL, Martins I, et al. Nonallele-specific silencing of mutant and wild-type huntingtin demonstrates therapeutic efficacy in Huntington’s disease mice. Mol Ther. 2009;17(6):1053–1063.
   PubMed Web of Science ®Google Scholar
• McBride JL, Pitzer MR, Boudreau RL, et al. Preclinical safety of RNAi-mediated HTT suppression in the rhesus macaque as a potential therapy for Huntington’s disease. Mol Ther. 2011;19(12):2152–2162.
   PubMed Web of Science ®Google Scholar
• Grondin R, Kaytor MD, Ai Y, et al. Six-month partial suppression of Huntingtin is well tolerated in the adult rhesus striatum. Brain. 2012;135(4):1197–1209.
   PubMedGoogle Scholar
• Stanek LM, Sardi SP, Mastis B, et al. Silencing mutant huntingtin by adeno-associated virus-mediated RNA interference ameliorates disease manifestations in the YAC128 mouse model of Huntington’s disease. Hum Gene Ther. 2014;25(5):461–474.
   PubMed Web of Science ®Google Scholar
• Johnson E, Chase K, McGowan S, et al. Safety of striatal infusion of siRNA in a transgenic Huntington’s disease mouse model. J Huntingtons Dis. 2015;4(3):219–229.
   PubMed Web of Science ®Google Scholar
• Keeler AM, Sapp E, Chase K, et al. Cellular analysis of silencing the Huntington’s disease gene using AAV9 mediated delivery of artificial micro RNA into the striatum of Q140/Q140 mice. J Huntingtons Dis. 2016;5(3):239–248.
   PubMed Web of Science ®Google Scholar
• Miniarikova J, Zimmer V, Martier R, et al. AAV5-miHTT gene therapy demonstrates suppression of mutant huntingtin aggregation and neuronal dysfunction in a rat model of Huntington’s disease. Gene Ther. 2017;24(10):630–639.
   PubMed Web of Science ®Google Scholar
• Evers MM, Miniarikova J, Juhas S, et al. AAV5-miHTT gene therapy demonstrates broad distribution and strong human mutant huntingtin lowering in a Huntington’s disease minipig model. Mol Ther. 2018;26(9):2163–2177.
   PubMed Web of Science ®Google Scholar
• Pfister EL, DiNardo N, Mondo E, et al. Artificial miRNAs reduce human mutant huntingtin throughout the striatum in a transgenic sheep model of Huntington’s disease. Hum Gene Ther. 2018;29(6):663–673.
   PubMed Web of Science ®Google Scholar
• Spronck EA, Brouwers CC, Vallès A, et al. AAV5-miHTT gene therapy demonstrates sustained huntingtin lowering and functional improvement in huntington disease mouse models. Mol Ther Methods Clin Dev. 2019;13:334–343.
   PubMed Web of Science ®Google Scholar
• Caron NS, Southwell AL, Brouwers CC, et al. Potent and sustained huntingtin lowering via AAV5 encoding miRNA preserves striatal volume and cognitive function in a humanized mouse model of Huntington disease. Nucleic Acids Res. 2020;48(1):36–54.
   PubMed Web of Science ®Google Scholar
• Casaca-Carreira J, Toonen LJ, Evers MM, et al. In vivo proof-of-concept of removal of the huntingtin caspase cleavage motif-encoding exon 12 approach in the YAC128 mouse model of Huntington’s disease. Biomed Pharmacother. 2016;84:93–96.
   PubMed Web of Science ®Google Scholar
• Ambesajir A, Kaushik A, Kaushik JJ, et al. RNA interference: A futuristic tool and its therapeutic applications. Saudi J Biol Sci. 2012;19(4):395–403.
   PubMed Web of Science ®Google Scholar
• Montgomery MK, Xu S, Fire A. RNA as a target of double-stranded RNA-mediated genetic interference in Caenorhabditis elegans. Proc Natl Acad Sci U S A. 1998;95(26):15502–15507.
   PubMed Web of Science ®Google Scholar
• Chen X, Mangala LS, Rodriguez-Aguayo C, et al. RNA interference-based therapy and its delivery systems. Cancer Metastasis Rev. 2018;37(1):107–124.
   PubMed Web of Science ®Google Scholar
• Awasthi R, Madan JR, Malipeddi H, et al. Therapeutic strategies for targeting non-coding RNAs with special emphasis on novel delivery systems. NCRI. 2019;3:1–7.
   Google Scholar
• Lam JK, Chow MY, Zhang Y, et al. siRNA versus miRNA as therapeutics for gene silencing. Mol Ther Nucleic Acids. 2015;4:e252.
   PubMedGoogle Scholar
• Wilson RC, Doudna JA. Molecular mechanisms of RNA interference. Annu Rev Biophys. 2013;42(1):217–239.
   PubMedGoogle Scholar
• Wolfe MS. The molecular and cellular basis of neurodegenerative diseases: underlying mechanisms. Amsterdam (The Netherlands): Academic Press, Elsevier Science & Technology Books; 2018.
   Google Scholar
• Setten RL, Rossi JJ, Han SP. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18:421–446.
   PubMed Web of Science ®Google Scholar
• Chernikov IV, Vlassov VV, Chernolovskaya EL. Current development of siRNA bioconjugates: from research to the clinic. Front Pharmacol. 2019;10:444.
   PubMed Web of Science ®Google Scholar
• Catalanotto C, Cogoni C, Zardo G. MicroRNA in control of gene expression: an overview of nuclear functions. Int J Mol Sci. 2016;17(10):1712.
   PubMed Web of Science ®Google Scholar
• O’Brien J, Hayder H, Zayed Y, et al. Overview of microRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018;9:402.
   Google Scholar
• Walayat A, Yang M, Xiao D. Therapeutic implication of miRNA in human disease. In: Sharad S, Kapur S, editors. Antisense therapy. London (UK): Intech Open; 2019.
   Google Scholar
• Ghosh R, Tabrizi SJ. Gene suppression approaches to neurodegeneration. Alzheimers Res Ther. 2017;9(1):82.
   PubMedGoogle Scholar
• Tabrizi SJ, Leavitt BR, Landwehrmeyer GB, et al. Targeting huntingtin expression in patients with Huntington’s disease. NEJM. 2019;380(24):2307–2316.
   PubMed Web of Science ®Google Scholar
• Zhou J, Rossi J. Aptamers as targeted therapeutics: current potential and challenges. Nat Rev Drug Discov. 2017;16(3):181.
   PubMed Web of Science ®Google Scholar
• Nimjee SM, White RR, Becker RC, et al. Aptamers as therapeutics. Annu Rev Pharmacol Toxicol. 2017;57(1):61–79.
   PubMedGoogle Scholar
• Chaudhary RK, Patel KA, Patel MK, et al. Inhibition of aggregation of mutant Huntingtin by nucleic acid aptamers in vitro and in a yeast model of Huntington’s disease. Mol Ther. 2015;23(12):1912–1926.
   PubMed Web of Science ®Google Scholar
• Patel KA, Chaudhary RK, Roy I. RNA aptamers rescue mitochondrial dysfunction in a yeast model of huntington’s disease. Mol Ther Nucleic Acids. 2018;12:45–56.
   PubMedGoogle Scholar
• Patel KA, Kolluri T, Jain S, et al. Designing aptamers which respond to intracellular oxidative stress and inhibit aggregation of mutant huntingtin. Free Radic Biol Med. 2018;120:311–316.
   PubMed Web of Science ®Google Scholar
• Shin B, Jung R, Oh H, et al. Novel DNA aptamers that bind to mutant huntingtin and modify its activity. Mol Ther Nucleic Acids. 2018;11:416–428.
   PubMedGoogle Scholar
• Khan E, Biswas S, Mishra SK, et al. Rationally designed small molecules targeting toxic CAG repeat RNA that causes Huntington’s disease (HD) and spinocerebellar ataxia (SCAs). Biochimie. 2019;163:21–32.
   PubMed Web of Science ®Google Scholar
• Khan E, Tawani A, Mishra SK, et al. Myricetin reduces toxic level of CAG repeats RNA in Huntington’s disease (HD) and spino cerebellar ataxia (SCAs). ACS Chem Biol. 2018;13(1):180–188.
   PubMed Web of Science ®Google Scholar
• Bowie LE, Maiuri T, Alpaugh M, et al. N6-furfuryladenine is protective in huntington’s disease models by signaling huntingtin phosphorylation. Proc Natl Acad Sci U S A. 2018;115(30):E7081–90.
   PubMed Web of Science ®Google Scholar
• Rath D, Amlinger L, Rath A, et al. The CRISPR-Cas immune system: biology, mechanisms and applications. Biochimie. 2015;117:119–128.
   PubMed Web of Science ®Google Scholar
• Yang S, Chang R, Yang H, et al. CRISPR/Cas9-mediated gene editing ameliorates neurotoxicity in mouse model of Huntington’s disease. J Clin Invest. 2017;127(7):2719–2724.
   PubMed Web of Science ®Google Scholar
• Monteys AM, Ebanks SA, Keiser MS, et al. CRISPR/Cas9 editing of the mutant huntingtin allele in vitro and in vivo. Mol Ther. 2017;25(1):12–23.
   PubMed Web of Science ®Google Scholar
• Merienne N, Vachey G, de Longprez L, et al. The self-inactivating KamiCas9 system for the editing of CNS disease genes. Cell Rep. 2017;20(12):2980–2991.
   PubMed Web of Science ®Google Scholar
• Ekman FK, Ojala DS, Adil MM, et al. CRISPR-cas9-mediated genome editing increases lifespan and improves motor deficits in a Huntington’s disease mouse model. Mol Ther Nucleic Acids. 2019;17:829–839.
   PubMedGoogle Scholar
• Lino CA, Harper JC, Carney JP, et al. Delivering CRISPR: a review of the challenges and approaches. Drug Deliv. 2018;25(1):1234–1257.
   PubMed Web of Science ®Google Scholar
• Hossain MA, Barrow JJ, Shen Y, et al. Artificial zinc finger DNA binding domains: versatile tools for genome engineering and modulation of gene expression. J Cell Biochem. 2015;116(11):2435–2444.
   PubMed Web of Science ®Google Scholar
• Garriga-Canut M, Agustín-Pavón C, Herrmann F, et al. Synthetic zinc finger repressors reduce mutant huntingtin expression in the brain of R6/2 mice. Proc Natl Acad Sci U S A. 2012;109(45):E3136–145.
   PubMed Web of Science ®Google Scholar
• Agustín-Pavón C, Mielcarek M, Garriga-Canut M, et al. Deimmunization for gene therapy: host matching of synthetic zinc finger constructs enables long-term mutant Huntingtin repression in mice. Mol Neurodegener. 2016;11(1):64.
   PubMedGoogle Scholar
• Zeitler B, Froelich S, Marlen K, et al. Allele-selective transcriptional repression of mutant HTT for the treatment of Huntington’s disease. Nat Med. 2019;25(7):1131–1142.
   PubMed Web of Science ®Google Scholar
• Nakamori M, Panigrahi GB, Lanni S, et al. A slipped-CAG DNA-binding small molecule induces trinucleotide-repeat contractions in vivo. Nat Gen. 2020;52(2):146–159.
   PubMed Web of Science ®Google Scholar
• Crotti A, Benner C, Kerman BE, et al. Mutant Huntingtin promotes autonomous microglia activation via myeloid lineage-determining factors. Nat Neurosci. 2014;17(4):513.
   PubMed Web of Science ®Google Scholar
• Cicchetti F, Lacroix S, Cisbani G, et al. Mutant huntingtin is present in neuronal grafts in Huntington disease patients. Ann Neurol. 2014;76(1):31–42.
   PubMed Web of Science ®Google Scholar
• Tang BL. Unconventional secretion and intercellular transfer of mutant huntingtin. Cells. 2018;7(6):59.
   Web of Science ®Google Scholar
• Southwell AL, Khoshnan A, Dunn DE, et al. Intrabodies binding the proline-rich domains of mutant huntingtin increase its turnover and reduce neurotoxicity. J Neurosci. 2008;28(36):9013–9020.
   PubMed Web of Science ®Google Scholar
• Southwell AL, Ko J, Patterson PH. Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington’s disease. J Neurosci. 2009;29(43):13589–13602.
   PubMed Web of Science ®Google Scholar
• Amaro IA, Henderson LA. An intrabody drug (rAAV6-INT41) reduces the binding of N-terminal Huntingtin fragment (s) to DNA to basal levels in PC12 cells and delays cognitive loss in the R6/2 animal model. J Neurodegener Dis. 2016;2016:7120753.
   PubMedGoogle Scholar
• Snyder-Keller A, McLear JA, Hathorn T, et al. Early or late-stage anti-N-terminal Huntingtin intrabody gene therapy reduces pathological features in B6. HDR6/1 mice. J Neuropathol Exp Neurol. 2010;69(10):1078–1085.
   PubMed Web of Science ®Google Scholar
• Wolfgang WJ, Miller TW, Webster JM, et al. Suppression of Huntington’s disease pathology in Drosophila by human single-chain Fv antibodies. Proc Natl Acad Sci U S A. 2005;102(32):11563–11568.
   PubMed Web of Science ®Google Scholar
• Zha J, Liu XM, Zhu J, et al. A scFv antibody targeting common oligomeric epitope has potential for treating several amyloidoses. Sci Rep. 2016;6(1):36631.
   PubMedGoogle Scholar
• Ramsingh AI, Manley K, Rong Y, et al. Transcriptional dysregulation of inflammatory/immune pathways after active vaccination against Huntington′ s disease. Hum Mol Genet. 2015;24(21):6186–6197.
   PubMed Web of Science ®Google Scholar
• Masnata M, Sciacca G, Maxan A, et al. Demonstration of prion-like properties of mutant huntingtin fibrils in both in vitro and in vivo paradigms. Acta Neuropathol. 2019;137(6):981–1001.
   PubMed Web of Science ®Google Scholar
• Garcia-Miralles M, Hong X, Tan LJ, et al. Laquinimod rescues striatal, cortical and white matter pathology and results in modest behavioural improvements in the YAC128 model of Huntington disease. Sci Rep. 2016;6(1):31652.
   PubMedGoogle Scholar
• Garcia-Miralles M, Yusof NA, Tan JY, et al. Laquinimod treatment improves myelination deficits at the transcriptional and ultrastructural levels in the YAC128 mouse model of Huntington disease. Mol. Neurobiol. 2019;56(6):4464–4478.
   PubMed Web of Science ®Google Scholar
• Ellrichmann G, Blusch A, Fatoba O, et al. Laquinimod treatment in the R6/2 mouse model. Sci Rep. 2017;7(1):4947.
   PubMedGoogle Scholar
• Southwell AL, Franciosi S, Villanueva EB, et al. Anti-semaphorin 4D immunotherapy ameliorates neuropathology and some cognitive impairment in the YAC128 mouse model of Huntington disease. Neurobiol Dis. 2015;76:46–56.
   PubMed Web of Science ®Google Scholar
• Hsiao HY, Chiu FL, Chen CM, et al. Inhibition of soluble tumor necrosis factor is therapeutic in Huntington’s disease. Hum Mol Genet. 2014;23(16):4328–4344.
   PubMed Web of Science ®Google Scholar
• Pido-Lopez J, Tanudjojo B, Farag S, et al. Inhibition of tumour necrosis factor alpha in the R6/2 mouse model of Huntington’s disease by etanercept treatment. Sci Rep. 2019;9(1):7202.
   PubMedGoogle Scholar